Research programme: AAV-based gene therapies - Neuralgene

Drug Profile

Research programme: AAV-based gene therapies - Neuralgene

Alternative Names: PRCN 226; PRCN 408; PRCN 829

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuralgene
  • Developer Neuralgene; Precision StemCell
  • Class Gene therapies
  • Mechanism of Action Complement factor H modulators; Complement system protein inhibitors; Gene modulators; Growth factor receptor modulators; Neurogenesis stimulants; TDP-43 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Macular degeneration; Neurodegenerative disorders; Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in Colombia
  • 16 Jul 2016 No recent reports of development identified for research development in Amyotrophic-lateral-sclerosis in Colombia
  • 16 Jul 2016 No recent reports of development identified for research development in Macular-degeneration in Colombia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top